开元官网登录入口

Shanghai, China - At the opening ceremony of the WAIC on September 1, 2022, Toumai^® Laparoscopic Surgical Robot developed by Shanghai MicroPort MedBot (Group) Co., Ltd. (“MicroPort^® MedBot^®)”) won the SAIL Award (Super AI Leader), the highest honor of the conference. The conference commented that Toumai^® as is a laparoscopic surgical robot independently developed by China, which indicates our domestic surgical robots are capable of assisting doctors to complete complex surgeries in narrow spaces.

WAIC is approved by the State Council and hosted by the National Development and Reform Commission, Ministry of Science and Technology, Ministry of Industry and Information Technology, Cyberspace Administration of China, Chinese Academy of Sciences, Chinese Academy of Engineering, China Association for Science and Technology and the Shanghai Municipal People's Government. As one of the most influential events in the global AI field, it is reputed as the "Oscar" in the AI field of the industry.

SAIL Award is the official award of the highest specification in the AI field of China. It is established to celebrate global AI innovation projects that lead technological innovation and transformation, and create a better future. The 2022 SAIL Award continues to lead the industry trends and focuses on the hot fields. More than 800 projects from top global enterprises, international prestigious universities and science institutes competes for TOP 30. The contests involve preliminary assessment, re-evaluation and final review conducted on the principles of independence, fairness and profession. Finally, Toumai^® Laparoscopic Surgical Robot stood out among a large number of projects and won one of the five SAIL awards as an excellent product in the smart medical fields. At the opening ceremony of the WAIC, Mr. Yu Liu, Executive Vice President and Chief Commercial Officer of MicroPort^® MedBot^® , as a representative to receive the award.

For the name of SAIL, the letter "S" represents "Superior", indicating the leading position of the award in the industry; "A" implies "Applicative", highlighting SAIL's high expectation on AI technology to empower the application in the realm of economy and society; "I" refers to "Innovative", bringing to the fore the theoretical and technical innovation requirements for the participating projects; "L" stands for "Leading", manifesting that SAIL Awards aim to incorporate the most outstanding trailblazers in artificial intelligence in the international arena. SAIL also means embarking on a long journey, representing the hope that AI will start here from Shanghai, achieve rapid growth and bring more benefits to the world.

The winner, MicroPort^® Toumai^® is a domestic laparoscopic surgical robot self-developed by Shanghai MicroPort MedBot (Group) Co., Ltd and approved for marketing by the National Medical Products Administration (NMPA) in January 2022, making it the first and only four-arm laparoscopic robot developed by a Chinese company and approved for marketing so far. MicroPort^® Toumai^® Laparoscopic Surgical Robot is a high-end medical device that integrates multidisciplinary high technology, consisting of the surgeon console, the patient cart and the image vehicle. By tele-operation technology, Toumai® enables surgeon to sit outside of the aseptic surgery area to conduct the surgery, thus it reduces the burden of surgeons. Toumai^® boasts clinical advantages such as three-dimensional realistic surgical fields and highly flexible wrist surgical instruments, and has showcased its effectiveness and safety in clinical trials, making it widely applicable in all kinds of surgeries, including Urology Surgery (NMPA approval).

Powered by excellent quality and innovative technologies, Toumai^® Laparoscopic Surgical Robot has won multiple significant awards in the first half of this year. Now, it has again recognized by the industry and other factors with the SAIL Award in the field of AI.

In March 2022, thanks to its unique design and extremely high clinical value, Toumai^® stood out from nearly 10,000 works from more than 60 countries around the world and was the first laparoscopic surgical robot in Asia to win the Red Dot design award.

In July, 2022, MicroPort^® MedBot^® was named one of the 50 Smartest Companies in 2021 by MIT Technology Review ("MIT TR50"). The reason for recommendation is: Toumai^® Laparoscopic Surgical Robot features the only force displaying function in the world. It has solved the technology bottleneck of operation force displaying that has bothered the laparoscopic surgical robot field for decades. It also leads the smart transformation in the medical field with excellent robotic technologies and innovation capacities.

Toumai^® has been frequently recognized by various social sectors for several reasons. The core one is that it has continuously been pushing the boundaries of the clinical medicine fields, and leading the innovative development of self-developed surgical robots in China. In this way, it enables more convenient access to superior medical resources for remote areas, reduces the gap of hierarchical diagnosis and treatment, and also reduces the economic burden of patients.

In June 2022, MicroPort^® Toumai^® Laparoscopic Surgical Robot successfully completed two ultra-long-distance urology surgeries, spanning nearly 5,000 kilometers from Kizilsu Kirghiz Autonomous Prefecture of Xinjiang Uygur Autonomous Region to Nanjing of Jiangsu Province, thus realizing the world’s longest distance 5G remote robotic surgery so far and demonstrating China’s breakthrough and leadership in 5G ultra-long-distance surgery. This greatly helps solve the surgical technology bottleneck of hospitals in remote and less developed areas and makes it easier to conduct difficult and complex surgeries. Patients can also receive remote surgical treatment from top experts "without leaving their hometowns", and there is no need to seek medical treatment in other places in this scenario.

From June to August 2022, MicroPort^® Toumai^® successfully completed 50 difficult surgeries in Shandong Provincial Hospital in two months, and the average monthly surgical volume reached the level of the mature surgical products in the world. The product stability and performance advantages demonstrated by Toumai^® in the research and clinical projects show that "Intelligent Manufacturing in China" is reaching the international leading level in terms of precision and technology.

The SAIL Award has reflected the action and determination of MicroPort^® MedBot^® to promote the innovation and development of the self-developed surgical robot industry for the benefit of more patients. In the future, MicroPort^® MedBot^® will continue to devote to technological innovation and application, provide more efficient, comprehensive robotic intelligent surgical total solutions to the society, realizing the initial goal to "Make Surgery Easier, Safer and Less Invasive".